Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78238
Title:
Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience.
Authors:
Gowda, Raghavendra V; Henk, J Michael; Mais, Kathleen L; Sykes, Andrew J; Swindell, Ric; Slevin, Nicholas J ( 0000-0002-3367-7013 )
Abstract:
BACKGROUND AND PURPOSE: Radiotherapy for laryngeal carcinoma is conventionally given over a 6-7-week period. However, in a number of UK centres early lesions are treated over 3 weeks. We review recent results of this policy and discuss the reasons why short treatment times may be advantageous. MATERIALS AND METHODS: Two hundred patients (100 from each centre) with T1 glottic invasive squamous cell carcinoma treated with definitive radiotherapy between 1989 and 1997 were analysed. The median age was 68 years. All patients received once daily fractionation, 5 days a week to a total tumour dose of 50.0-52.5 Gy in 16 fractions over 21 days; the fraction size ranged from 3.12 to 3.28 Gy. The median follow-up period was 5 years and 10 months. RESULTS: The 5-year local control rates with radiotherapy for the whole group was 93%; there were 14 recurrences of which seven were salvaged by laryngectomy giving an ultimate local control of 96%. The 5-year overall survival was 80% and cause specific survival at 5 years was 97%. Univariate analysis revealed that T1 substaging (P=0.82) and anterior commissure involvement (P=0.47) did not significantly influence local control. A severe late radiation complication was seen in only one patient who continued to smoke heavily after treatment. There were no severe acute complications. CONCLUSIONS: Once daily radiotherapy over 3 weeks gives excellent local control in patients with T1 glottic squamous-cell carcinoma and has a low rate of severe complications. The short overall treatment time and large fraction size may be advantageous in radiotherapy of these well-differentiated tumours.
Affiliation:
Department of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK.
Citation:
Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience. 2003, 68 (2):105-11 Radiother Oncol
Journal:
Radiotherapy and Oncology
Issue Date:
Aug-2003
URI:
http://hdl.handle.net/10541/78238
PubMed ID:
12972304
Type:
Article
Language:
en
ISSN:
0167-8140
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGowda, Raghavendra V-
dc.contributor.authorHenk, J Michael-
dc.contributor.authorMais, Kathleen L-
dc.contributor.authorSykes, Andrew J-
dc.contributor.authorSwindell, Ric-
dc.contributor.authorSlevin, Nicholas J-
dc.date.accessioned2009-08-21T14:25:13Z-
dc.date.available2009-08-21T14:25:13Z-
dc.date.issued2003-08-
dc.identifier.citationThree weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience. 2003, 68 (2):105-11 Radiother Oncolen
dc.identifier.issn0167-8140-
dc.identifier.pmid12972304-
dc.identifier.urihttp://hdl.handle.net/10541/78238-
dc.description.abstractBACKGROUND AND PURPOSE: Radiotherapy for laryngeal carcinoma is conventionally given over a 6-7-week period. However, in a number of UK centres early lesions are treated over 3 weeks. We review recent results of this policy and discuss the reasons why short treatment times may be advantageous. MATERIALS AND METHODS: Two hundred patients (100 from each centre) with T1 glottic invasive squamous cell carcinoma treated with definitive radiotherapy between 1989 and 1997 were analysed. The median age was 68 years. All patients received once daily fractionation, 5 days a week to a total tumour dose of 50.0-52.5 Gy in 16 fractions over 21 days; the fraction size ranged from 3.12 to 3.28 Gy. The median follow-up period was 5 years and 10 months. RESULTS: The 5-year local control rates with radiotherapy for the whole group was 93%; there were 14 recurrences of which seven were salvaged by laryngectomy giving an ultimate local control of 96%. The 5-year overall survival was 80% and cause specific survival at 5 years was 97%. Univariate analysis revealed that T1 substaging (P=0.82) and anterior commissure involvement (P=0.47) did not significantly influence local control. A severe late radiation complication was seen in only one patient who continued to smoke heavily after treatment. There were no severe acute complications. CONCLUSIONS: Once daily radiotherapy over 3 weeks gives excellent local control in patients with T1 glottic squamous-cell carcinoma and has a low rate of severe complications. The short overall treatment time and large fraction size may be advantageous in radiotherapy of these well-differentiated tumours.en
dc.language.isoenen
dc.subjectLaryngeal Canceren
dc.subjectCancer Recurrenceen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshDose Fractionation-
dc.subject.meshFemale-
dc.subject.meshGlottis-
dc.subject.meshHumans-
dc.subject.meshLaryngeal Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshRetrospective Studies-
dc.subject.meshSurvival Rate-
dc.subject.meshTreatment Outcome-
dc.titleThree weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK.en
dc.identifier.journalRadiotherapy and Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.